HRP20161237T1 - Antimalarijski agensi - Google Patents

Antimalarijski agensi Download PDF

Info

Publication number
HRP20161237T1
HRP20161237T1 HRP20161237TT HRP20161237T HRP20161237T1 HR P20161237 T1 HRP20161237 T1 HR P20161237T1 HR P20161237T T HRP20161237T T HR P20161237TT HR P20161237 T HRP20161237 T HR P20161237T HR P20161237 T1 HRP20161237 T1 HR P20161237T1
Authority
HR
Croatia
Prior art keywords
phenyl
pyrazin
trifluoromethyl
amino
methanone
Prior art date
Application number
HRP20161237TT
Other languages
English (en)
Croatian (hr)
Inventor
Yassir YOUNIS
Kelly Chibale
Michael John Witty
David Waterson
Original Assignee
University Of Cape Town
Mmv Medicines For Malaria Venture
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Cape Town, Mmv Medicines For Malaria Venture filed Critical University Of Cape Town
Publication of HRP20161237T1 publication Critical patent/HRP20161237T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HRP20161237TT 2012-02-17 2013-02-15 Antimalarijski agensi HRP20161237T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261600324P 2012-02-17 2012-02-17
PCT/IB2013/051235 WO2013121387A1 (en) 2012-02-17 2013-02-15 Anti -malarial agents
EP13712926.8A EP2814820B1 (en) 2012-02-17 2013-02-15 Anti-malarial agents

Publications (1)

Publication Number Publication Date
HRP20161237T1 true HRP20161237T1 (hr) 2016-11-04

Family

ID=48014134

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161237TT HRP20161237T1 (hr) 2012-02-17 2013-02-15 Antimalarijski agensi

Country Status (20)

Country Link
US (1) US9266842B2 (enExample)
EP (1) EP2814820B1 (enExample)
JP (1) JP6226889B2 (enExample)
CN (1) CN104136426B (enExample)
BR (1) BR112014020212B1 (enExample)
CA (1) CA2864483A1 (enExample)
CY (1) CY1118074T1 (enExample)
DK (1) DK2814820T3 (enExample)
ES (1) ES2589283T3 (enExample)
HR (1) HRP20161237T1 (enExample)
HU (1) HUE029876T2 (enExample)
IN (1) IN2014MN01622A (enExample)
LT (1) LT2814820T (enExample)
ME (1) ME02535B (enExample)
PL (1) PL2814820T3 (enExample)
PT (1) PT2814820T (enExample)
SI (1) SI2814820T1 (enExample)
SM (1) SMT201600441B (enExample)
WO (1) WO2013121387A1 (enExample)
ZA (1) ZA201406786B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2589283T3 (es) * 2012-02-17 2016-11-11 University Of Cape Town Agentes anti-malaria
EP3118198A1 (en) 2015-07-13 2017-01-18 MMV Medicines for Malaria Venture Anti-malarial agents
WO2017067881A1 (en) * 2015-10-19 2017-04-27 Glaxosmithkline Intellectual Property Development Limited Pyrazine compounds for use in the treatment of parasitic protozoal infections
JP7057427B2 (ja) * 2018-01-24 2022-04-19 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 寄生虫感染の処置のための新規化合物
CN112142715A (zh) * 2020-10-10 2020-12-29 鲁南制药集团股份有限公司 一种2-氨基-5-杂环基取代的吡嗪衍生物及其用途
WO2023094305A1 (en) * 2021-11-23 2023-06-01 Glaxosmithkline Intellectual Property Development Limited Pyrazine compounds useful in the treatment of parasitic protozoal infection
CN119948032A (zh) 2022-08-09 2025-05-06 默克专利股份有限公司 呋喃并嘧啶衍生物
WO2024033280A1 (en) 2022-08-09 2024-02-15 Merck Patent Gmbh Furopyridin and furopyrimidin, inhibitors of pi4k, for use in the treatment of parasite infection and malaria

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4772690B2 (ja) * 2003-12-03 2011-09-14 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド チューブリン阻害剤
ATE456565T1 (de) * 2006-06-22 2010-02-15 Biovitrum Ab Publ Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
EP1900727A1 (en) * 2006-08-30 2008-03-19 Cellzome Ag Aminopyridine derivatives as kinase inhibitors
GB0625659D0 (en) * 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
EP2526090B1 (en) * 2010-01-18 2015-08-19 MMV Medicines for Malaria Venture New anti-malarial agents
EP2569286B1 (en) * 2010-05-12 2014-08-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
AU2012225805B2 (en) 2011-03-04 2017-03-02 Lexicon Pharmaceuticals, Inc. MST1 kinase inhibitors and methods of their use
ES2589283T3 (es) * 2012-02-17 2016-11-11 University Of Cape Town Agentes anti-malaria

Also Published As

Publication number Publication date
SI2814820T1 (sl) 2016-10-28
PT2814820T (pt) 2016-10-25
HK1202859A1 (en) 2015-10-09
BR112014020212B1 (pt) 2021-11-23
BR112014020212A8 (pt) 2018-01-23
CN104136426A (zh) 2014-11-05
HUE029876T2 (en) 2017-04-28
US20150031682A1 (en) 2015-01-29
EP2814820A1 (en) 2014-12-24
JP6226889B2 (ja) 2017-11-08
JP2015507004A (ja) 2015-03-05
WO2013121387A1 (en) 2013-08-22
US9266842B2 (en) 2016-02-23
CA2864483A1 (en) 2013-08-22
IN2014MN01622A (enExample) 2015-05-15
ES2589283T3 (es) 2016-11-11
LT2814820T (lt) 2016-10-25
CY1118074T1 (el) 2017-06-28
ME02535B (me) 2017-02-20
EP2814820B1 (en) 2016-07-20
SMT201600441B (it) 2017-01-10
PL2814820T3 (pl) 2017-01-31
ZA201406786B (en) 2015-06-24
DK2814820T3 (en) 2016-10-03
CN104136426B (zh) 2017-10-03

Similar Documents

Publication Publication Date Title
HRP20161237T1 (hr) Antimalarijski agensi
AU2014233414B2 (en) N-acyl-N'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
HRP20171453T1 (hr) Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za liječenje agregacije trombocita
SI3024819T1 (en) Glyoxamide-substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis B
PE20110835A1 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
MX393395B (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, método de preparación del mismo y usos médicos del mismo.
HRP20210459T1 (hr) Supstituirani derivati oksopiridina
RU2017122364A (ru) N-((гет)арилметил)-гетероарил-карбоксамидные соединения в качестве ингибиторов плазменного калликреина
AR086546A1 (es) Derivados de 7h-purin-8(9h)-ona como inhibidores de jak
PE20190336A1 (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
HRP20241768T1 (hr) Heterociklički spoj
ME02409B (me) Novi heterociklični derivati i njihova upotreba u tretmanu neuroloških poremećaja
JP2016506369A5 (enExample)
AU2018233402A1 (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
AR053195A1 (es) Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo
BR112014019478A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença.
AR078187A1 (es) Derivados heterociclicos de benzoxazepina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer.
SI2953948T1 (en) FLUORINATED INTEGRIN ANTAGONISTS
ME02664B (me) Derivati premeštanja piridina u toku transfekcije inhibitora (ret) kinaze
HRP20191826T4 (hr) Derivati n-piridinil acetamida kao inhibitori wnt signalnog puta
JP2016517417A5 (enExample)
NZ627750A (en) Carbamate compounds and of making and using same
HRP20200274T1 (hr) Terapeutski aktivni spojevi i postupci njihove uporabe
RU2019114600A (ru) Соединение аминопиразолопиримидина, используемое в качестве ингибитора тирозинкиназного рецептора нейротрофического фактора
UY33606A (es) DERIVADOS DE PIRAZINA COMO BLOQUEADORES DE ENaC